Implicity raises €35M to scale cardiac AI tied to 26% lower mortality
What's the deal? Implicity has raised €35 million in growth equity, co-led by IRIS and Five ArrowsDealroom has a profile for this one. Try Dealroom →. The Paris- and Cambridge, Massachusetts-based company builds AI platforms for cardiac device monitoring, with results tied to a 26% reduction in patient mortality.
Who's behind it? Founder Arnaud Rosier, an electrophysiologist with a PhD in knowledge engineering, started the company in 2016 after noticing device alerts were outpacing what clinics could handle. "I didn't become a doctor in order to deal with data. I became one so that I could treat patients," he said. Nine years on, he still practises part-time while running Implicity.
What does it build? A data platform pulls information from five device manufacturers and hospital records. Signal HF predicts which patients may need hospitalisation and won FDA approval about two years ago; a second "productivity AI" cuts false alarms using medication and clinical history.
By the numbers. The round pushes Implicity's total raised since 2016 to roughly $69 million, following a $23 million Series A in April 2022 backed by Crédit Mutuel InnovationDealroom has a profile for this one. Try Dealroom → and Bpifrance. IRIS, a growth investor with offices in Paris, Berlin, and Munich, led alongside Five Arrows, part of Rothschild & Co.Dealroom has a profile for this one. Try Dealroom →'s alternative assets division.
What's the money for? Implicity plans to expand in the United States and Germany, build commercial teams, and pursue acquisitions. It employs around 120 to 125 people, including 15 in the US and four in Germany, with the rest in France.
Not private equity. Rosier stresses the deal keeps founders in control. "We aren't really in the private equity business," he said, adding that Implicity avoided giving up a majority stake and chose investors for their experience scaling European companies in the US.
What could go wrong? Rosier calls the US "a huge market but one which is very difficult to enter." Rivals Murj and PaceMateDealroom has a profile for this one. Try Dealroom → have raised $8.5 million and $8 million respectively — smaller sums, but they compete for the same clinics.
The signal: Implicity's raise lands among the larger European healthtech rounds, reflecting investor appetite for medical AI that shows clinical outcomes rather than software that only reviews device data. With FDA-cleared products and a mortality claim behind it, the company is betting proven results can pry open the US market.
Image credit: Implicity
